PortalPublikationenIdentification of an immunogenic HLA-A*0201-binding T-cell e...

Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2

Standard

Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. / Asemissen, Anne Marie; Haase, Doreen; Stevanovic, Stefan; Bauer, Sandra; Busse, Antonia; Thiel, Eckhard; Rammensee, Hans-Georg; Keilholz, Ulrich; Scheibenbogen, Carmen.

in: J IMMUNOTHER, Jahrgang 32, Nr. 4, 05.2009, S. 370-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Asemissen, AM, Haase, D, Stevanovic, S, Bauer, S, Busse, A, Thiel, E, Rammensee, H-G, Keilholz, U & Scheibenbogen, C 2009, 'Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2', J IMMUNOTHER, Jg. 32, Nr. 4, S. 370-5. https://doi.org/10.1097/CJI.0b013e31819d4e09

APA

Asemissen, A. M., Haase, D., Stevanovic, S., Bauer, S., Busse, A., Thiel, E., Rammensee, H-G., Keilholz, U., & Scheibenbogen, C. (2009). Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. J IMMUNOTHER, 32(4), 370-5. https://doi.org/10.1097/CJI.0b013e31819d4e09

Vancouver

Asemissen AM, Haase D, Stevanovic S, Bauer S, Busse A, Thiel E et al. Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. J IMMUNOTHER. 2009 Mai;32(4):370-5. https://doi.org/10.1097/CJI.0b013e31819d4e09

Bibtex

@article{4d898d01f000456db29b25ae7fad60b0,
title = "Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2",
abstract = "PAX2 is a transcription factor and member of the highly conserved family of paired box genes. PAX2 is aberrantly expressed in a variety of solid and hematologic malignancies. PAX2 regulates the transcription factor Wilms tumor gene 1, which is a promising target of cancer immunotherapy. The aim of this study was to apply a modified reverse immunology strategy to identify immunogenic epitopes of PAX2 which could be useful for cancer immunotherapy. Thirteen potential HLA-A*0201 epitopes were predicted by a major histocompatibility complex binding algorithm (SYFPEITHI) and a proteasome cleavage algorithm (PAProC) and screened for recognition by T cells from HLA-A*02-positive cancer patients using intracellular cytokine cytometry. Epitope-specific T cells were generated from CD4CD25 regulatory T-cell-depleted peripheral blood mononuclear cell. Nine of 20 colorectal cancer patients, 1 of 13 renal cell carcinoma patients, and 2 of 17 lymphoma patients had a spontaneous CD8 T-cell response toward at least 1 of 6 PAX2 peptide pools. None of the 20 healthy subjects showed reactivity toward PAX2. PAX2.337-345 (TLPGYPPHV)-specific T cells could repeatedly be generated, which specifically lysed the PAX2 expressing colorectal tumor cell line SW480. In this study, a modified reverse immunology strategy was employed to identify a first immunogenic HLA-A*0201 restricted T-cell epitope and natural ligand of the tumor antigen PAX2. Thus, PAX2 is another embryonic transcription factor, which is of potential interest as immunotherapy target antigen.",
keywords = "Algorithms, Amino Acid Sequence, CD8-Positive T-Lymphocytes/immunology, Carcinoma, Renal Cell/immunology, Cell Line, Tumor, Colorectal Neoplasms/immunology, Epitopes, T-Lymphocyte/immunology, HLA-A Antigens/immunology, HLA-A2 Antigen, Humans, Lymphoma/immunology, Molecular Sequence Data, Nuclear Proteins/genetics, PAX2 Transcription Factor/immunology, Peptides/immunology",
author = "Asemissen, {Anne Marie} and Doreen Haase and Stefan Stevanovic and Sandra Bauer and Antonia Busse and Eckhard Thiel and Hans-Georg Rammensee and Ulrich Keilholz and Carmen Scheibenbogen",
year = "2009",
month = may,
doi = "10.1097/CJI.0b013e31819d4e09",
language = "English",
volume = "32",
pages = "370--5",
journal = "J IMMUNOTHER",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2

AU - Asemissen, Anne Marie

AU - Haase, Doreen

AU - Stevanovic, Stefan

AU - Bauer, Sandra

AU - Busse, Antonia

AU - Thiel, Eckhard

AU - Rammensee, Hans-Georg

AU - Keilholz, Ulrich

AU - Scheibenbogen, Carmen

PY - 2009/5

Y1 - 2009/5

N2 - PAX2 is a transcription factor and member of the highly conserved family of paired box genes. PAX2 is aberrantly expressed in a variety of solid and hematologic malignancies. PAX2 regulates the transcription factor Wilms tumor gene 1, which is a promising target of cancer immunotherapy. The aim of this study was to apply a modified reverse immunology strategy to identify immunogenic epitopes of PAX2 which could be useful for cancer immunotherapy. Thirteen potential HLA-A*0201 epitopes were predicted by a major histocompatibility complex binding algorithm (SYFPEITHI) and a proteasome cleavage algorithm (PAProC) and screened for recognition by T cells from HLA-A*02-positive cancer patients using intracellular cytokine cytometry. Epitope-specific T cells were generated from CD4CD25 regulatory T-cell-depleted peripheral blood mononuclear cell. Nine of 20 colorectal cancer patients, 1 of 13 renal cell carcinoma patients, and 2 of 17 lymphoma patients had a spontaneous CD8 T-cell response toward at least 1 of 6 PAX2 peptide pools. None of the 20 healthy subjects showed reactivity toward PAX2. PAX2.337-345 (TLPGYPPHV)-specific T cells could repeatedly be generated, which specifically lysed the PAX2 expressing colorectal tumor cell line SW480. In this study, a modified reverse immunology strategy was employed to identify a first immunogenic HLA-A*0201 restricted T-cell epitope and natural ligand of the tumor antigen PAX2. Thus, PAX2 is another embryonic transcription factor, which is of potential interest as immunotherapy target antigen.

AB - PAX2 is a transcription factor and member of the highly conserved family of paired box genes. PAX2 is aberrantly expressed in a variety of solid and hematologic malignancies. PAX2 regulates the transcription factor Wilms tumor gene 1, which is a promising target of cancer immunotherapy. The aim of this study was to apply a modified reverse immunology strategy to identify immunogenic epitopes of PAX2 which could be useful for cancer immunotherapy. Thirteen potential HLA-A*0201 epitopes were predicted by a major histocompatibility complex binding algorithm (SYFPEITHI) and a proteasome cleavage algorithm (PAProC) and screened for recognition by T cells from HLA-A*02-positive cancer patients using intracellular cytokine cytometry. Epitope-specific T cells were generated from CD4CD25 regulatory T-cell-depleted peripheral blood mononuclear cell. Nine of 20 colorectal cancer patients, 1 of 13 renal cell carcinoma patients, and 2 of 17 lymphoma patients had a spontaneous CD8 T-cell response toward at least 1 of 6 PAX2 peptide pools. None of the 20 healthy subjects showed reactivity toward PAX2. PAX2.337-345 (TLPGYPPHV)-specific T cells could repeatedly be generated, which specifically lysed the PAX2 expressing colorectal tumor cell line SW480. In this study, a modified reverse immunology strategy was employed to identify a first immunogenic HLA-A*0201 restricted T-cell epitope and natural ligand of the tumor antigen PAX2. Thus, PAX2 is another embryonic transcription factor, which is of potential interest as immunotherapy target antigen.

KW - Algorithms

KW - Amino Acid Sequence

KW - CD8-Positive T-Lymphocytes/immunology

KW - Carcinoma, Renal Cell/immunology

KW - Cell Line, Tumor

KW - Colorectal Neoplasms/immunology

KW - Epitopes, T-Lymphocyte/immunology

KW - HLA-A Antigens/immunology

KW - HLA-A2 Antigen

KW - Humans

KW - Lymphoma/immunology

KW - Molecular Sequence Data

KW - Nuclear Proteins/genetics

KW - PAX2 Transcription Factor/immunology

KW - Peptides/immunology

U2 - 10.1097/CJI.0b013e31819d4e09

DO - 10.1097/CJI.0b013e31819d4e09

M3 - SCORING: Journal article

C2 - 19342968

VL - 32

SP - 370

EP - 375

JO - J IMMUNOTHER

JF - J IMMUNOTHER

SN - 1524-9557

IS - 4

ER -